Tirzepatide drives weight loss in people with obesity due to MC4R deficiency

IF 50 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nature Medicine Pub Date : 2025-09-05 DOI:10.1038/s41591-025-03915-0

引用次数: 0

Abstract

We studied people with obesity involved in the SURMOUNT-1 trial of the dual GLP-1 and GIP receptor agonist, tirzepatide. People with pathogenic variants of the gene encoding the melanocortin 4 receptor (MC4R) lost a similar amount of weight to people with an intact gene, demonstrating that tirzepatide is effective in MC4R deficiency.

Abstract Image

查看原文本刊更多论文

替西帕肽促进因MC4R缺乏而肥胖的人的体重减轻

我们研究了参与SURMOUNT-1试验的肥胖患者，该试验使用GLP-1和GIP受体激动剂替西肽。携带黑素皮质素4受体（MC4R）编码基因致病性变异的人与携带完整基因的人体重下降相似，这表明替西帕肽对MC4R缺乏症有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.